CARM (CARISMA Therapeutics) Buyback Yield %: 9.02 (As of Jul. 09, 2026)


What is CARISMA Therapeutics Buyback Yield %?

CARISMA Therapeutics CARM -5.17% Buyback Yield % is 9.02 as of Jul. 09, 2026. The stock has 3 warning signs investors should review. Among 741 Biotechnology companies, CARISMA Therapeutics ranks better than 99.46% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

CARISMA Therapeutics's current buyback yield was 9.02%.

CARISMA Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics Buyback Yield % Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Buyback Yield %
0.00 0.00 0.00 -26.25 -13.68

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.89 -13.68 -0.82 -0.65 0.20

CARM vs SCPX, CYTOF, CNBX: Buyback Yield % Comparison

For the Biotechnology subindustry, CARISMA Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's Buyback Yield % falls into.


CARISMA Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

CARISMA Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 2.392) / 17.4849
=-13.68%

CARISMA Therapeutics's annualized Buyback Yield for the quarter that ended in Sep. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + -0.023) / 11.449912
=0.20%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 9.02 mean?
CARISMA Therapeutics (CARM) has a Buyback Yield % of 9.02 as of Jul. 09, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on CARISMA Therapeutics and its competitors. According to the industry distribution chart, CARISMA Therapeutics ranks #4 out of 741 companies in the Biotechnology industry, placing it in the top 0.5%.
Is CARISMA Therapeutics' Buyback Yield % too high?
CARISMA Therapeutics' current Buyback Yield % is 9.02. Based on the distribution chart, CARISMA Therapeutics ranks #4 out of 741 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does CARISMA Therapeutics' Buyback Yield % compare to SCPX and CYTOF?
According to the Biotechnology industry distribution chart, CARISMA Therapeutics ranks #4 out of 741 companies for Buyback Yield %. This places CARISMA Therapeutics in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current Buyback Yield % is 9.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.9% below its estimated fair value. The current Buyback Yield % is 9.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current Buyback Yield % is 9.02 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.